T/FIF Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: NeuroInvestment who wrote (804)	4/18/1999 12:15:00 AM
From: Miljenko Zuanic	Read Replies (1) of 1073

BJ, NI, Rick,... Thanks. <<Janssen has completed three Phase I safety trials totalling 80 patients; there does not appear to be any sedation, abuse, or tolerance, the compound's blood brain barrier access is good.>> Any opinion why Jansenn choose first open label major depression PII tria? Are they still searching for optimal dose/schedules or some issue(s) on drug pharmacology are/were not yet clear? <<There has been increased interest in the field in the application of CRF modulation to Post-Traumatic Stress Disorder (PTSD), a disorder wherein anxiety is ubiquitous, and depression frequent. >> Does anyone (except J&J, pharma or bios) have CRFr antagonist candidate near or at early stage clinical trial for anxiety/depression? TIA Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next